JMIR dermatology · 2026
Topical Recombinant Collagen Following Fractional Radio Frequency Microneedling for Nonsurgical Facelift: Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Thien-Chong Marcus, Ong Yizhi
Аннотация
BACKGROUND: Fractional radio frequency microneedling (FRM) is an effective nonsurgical facelift modality supported by growing clinical evidence. While generally well tolerated, postprocedural erythema, pain, swelling, and bruising typically last up to 7 days. Other serious complications include prolonged swelling, infection, persistent grid mark, burns, and hypo- or hyperpigmentation. Recombinant human collagen has demonstrated potent wound-healing and anti-inflammatory properties, which could be harnessed for post-FRM recovery.
OBJECTIVE: To date, there is a lack of published studies evaluating the use of topical agents to improve postprocedural recovery following FRM. This case report describes the early experience of using topical recombinant collagen post FRM for nonsurgical facelift.
METHODS: Two 40-year-old female patients with Fitzpatrick skin type IV underwent FRM for nonsurgical facelift. The procedure was performed with standard energy settings. Immediately post procedure, topical recombinant collagen was applied to the treated areas. Either clinical photography or cross-polarized imaging was used to objectively capture the changes in facial erythema and swelling.
RESULTS: Both cases demonstrated a marked reduction of erythema and inflammation within 1 to 2 hours after application of topical recombinant collagen. These observations appeared earlier compared to the typical timeframe of 1 to 3 days. No adverse events were reported.
CONCLUSIONS: Topical recombinant collagen application post FRM was associated with an early reduction of skin erythema and inflammation.
OBJECTIVE: To date, there is a lack of published studies evaluating the use of topical agents to improve postprocedural recovery following FRM. This case report describes the early experience of using topical recombinant collagen post FRM for nonsurgical facelift.
METHODS: Two 40-year-old female patients with Fitzpatrick skin type IV underwent FRM for nonsurgical facelift. The procedure was performed with standard energy settings. Immediately post procedure, topical recombinant collagen was applied to the treated areas. Either clinical photography or cross-polarized imaging was used to objectively capture the changes in facial erythema and swelling.
RESULTS: Both cases demonstrated a marked reduction of erythema and inflammation within 1 to 2 hours after application of topical recombinant collagen. These observations appeared earlier compared to the typical timeframe of 1 to 3 days. No adverse events were reported.
CONCLUSIONS: Topical recombinant collagen application post FRM was associated with an early reduction of skin erythema and inflammation.